Substance (Drug) Abuse - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 88 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Substance (Drug) Abuse - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Substance (Drug) Abuse - Pipeline Review, H2 2014', provides an overview of the Substance (Drug) Abuse's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Substance (Drug) Abuse, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Substance (Drug) Abuse and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Substance (Drug) Abuse
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Substance (Drug) Abuse and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Substance (Drug) Abuse products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Substance (Drug) Abuse pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Substance (Drug) Abuse
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Substance (Drug) Abuse pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Substance (Drug) Abuse Overview 9
Therapeutics Development 10
Pipeline Products for Substance (Drug) Abuse - Overview 10
Pipeline Products for Substance (Drug) Abuse - Comparative Analysis 11
Substance (Drug) Abuse - Therapeutics under Development by Companies 12
Substance (Drug) Abuse - Therapeutics under Investigation by Universities/Institutes 14
Substance (Drug) Abuse - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Substance (Drug) Abuse - Products under Development by Companies 19
Substance (Drug) Abuse - Products under Investigation by Universities/Institutes 20
Substance (Drug) Abuse - Companies Involved in Therapeutics Development 21
Teva Pharmaceutical Industries Limited 21
Addex Therapeutics Ltd 22
Snowdon Inc. 23
Grunenthal GmbH 24
Charleston Laboratories, Inc. 25
Reckitt Benckiser Pharmaceutical, Inc. 26
AllTranz, Inc. 27
InterveXion Therapeutics LLC 28
P2D Bioscience 29
Foresee Pharmaceuticals, LLC 30
Substance (Drug) Abuse - Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 35
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
Icariin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
L-Tetrahydropalmatine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
RBP-8000 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
hydrocodone bitartrate ER - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Ch-mAb7F9 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ADX-88178 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ADX-71441 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Small Molecules for Neurological Disorders - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ADX-71743 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Vaccine for Drug Abuse - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecules to Inhibit DAT for Cocaine Addiction and Cocaine Abuse - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Enzyme for Cocaine Addiction - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Vaccine for Methamphetamine Abuse - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
dronabinol - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CLBPC - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
CLFTC - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CLHMC - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
CLOXC - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CLHDC - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
VU-0463841 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
RO-656570 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
2E2 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
FP-004 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecule to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Drug to Inhibit Mu Opioid Receptor for Drug Abuse and Alcohol Addiction - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Substance (Drug) Abuse - Recent Pipeline Updates 73
Substance (Drug) Abuse - Dormant Projects 78
Substance (Drug) Abuse - Product Development Milestones 79
Featured News & Press Releases 79
Jul 08, 2014: FDA Grants Priority Review Designation for Purdue Pharma's Once-Daily Hydrocodone Bitartrate Extended-Release Tablets Formulated with Abuse-Deterrent Properties 79
Apr 30, 2014: Purdue Pharma Submits NDA For Once-Daily Hydrocodone Bitartrate Extended-Release Tablets Formulated To Incorporate Abuse-Deterrent Properties 79
Jul 29, 2013: Signature Therapeutics Receives BrIDGs Award to Advance Its Abuse-Deterrent Oxycodone, PF614 81
Jun 17, 2013: Purdue Pharma Announces Presentation Of Poster On OxyContin At 75th CPDD Annual Meeting 82
Dec 20, 2012: Acura Pharma Submits Investigational New Drug Application 82
Dec 20, 2012: Addex Scientists Discover And Characterize First Potent And Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 Receptor 83
Oct 29, 2012: Addex Therapeutics Announces Positive Preclinical Data For ADX71441 For Treatment Of Alcoholism 84
Mar 29, 2011: Catalyst Announces Commencement Of CPP-109 Investigator-Sponsored Study In Cocaine And Alcohol Co-Dependent Patients 84
Mar 09, 2011: MediciNova Receives Notice Of Allowance For Method Of Treating Drug Addiction 85
Dec 09, 2010: Catalyst Reports Canadian Patent For CPP-109 For Prevention Of Addiction In Pain Management 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 88
Disclaimer 88

List of Tables
Number of Products under Development for Substance (Drug) Abuse, H2 2014 10
Number of Products under Development for Substance (Drug) Abuse - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 15
Comparative Analysis by Late Stage Development, H2 2014 16
Comparative Analysis by Clinical Stage Development, H2 2014 17
Comparative Analysis by Early Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Investigation by Universities/Institutes, H2 2014 20
Substance (Drug) Abuse - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 21
Substance (Drug) Abuse - Pipeline by Addex Therapeutics Ltd, H2 2014 22
Substance (Drug) Abuse - Pipeline by Snowdon Inc., H2 2014 23
Substance (Drug) Abuse - Pipeline by Grunenthal GmbH, H2 2014 24
Substance (Drug) Abuse - Pipeline by Charleston Laboratories, Inc., H2 2014 25
Substance (Drug) Abuse - Pipeline by Reckitt Benckiser Pharmaceutical, Inc., H2 2014 26
Substance (Drug) Abuse - Pipeline by AllTranz, Inc., H2 2014 27
Substance (Drug) Abuse - Pipeline by InterveXion Therapeutics LLC, H2 2014 28
Substance (Drug) Abuse - Pipeline by P2D Bioscience, H2 2014 29
Substance (Drug) Abuse - Pipeline by Foresee Pharmaceuticals, LLC, H2 2014 30
Assessment by Monotherapy Products, H2 2014 31
Number of Products by Stage and Target, H2 2014 34
Number of Products by Stage and Mechanism of Action, H2 2014 37
Number of Products by Stage and Route of Administration, H2 2014 39
Number of Products by Stage and Molecule Type, H2 2014 41
Substance (Drug) Abuse Therapeutics - Recent Pipeline Updates, H2 2014 73
Substance (Drug) Abuse - Dormant Projects, H2 2014 78